Abbott's Whole-Genome Oncodetect Test Lifts Colorectal Cancer Recurrence Sensitivity by 30 Points

Abbott says its whole-genome sequencing (WGS) version of the Oncodetect molecular residual disease test detected colorectal cancer recurrence within two years of surgery with a 30-percent absolute improvement in sensitivity over the whole-exome sequencing (WES) version. The data from the Beta-CORRECT study were presented at the European Society for Medical Oncology (ESMO) Congress.
- Abbott's WGS Oncodetect test reached 72.2% sensitivity for recurrence within two years, versus 42.2% for the WES version.
- The Beta-CORRECT study analyzed post-surgical samples from 279 colorectal cancer patients.
- Detectable post-surgery ctDNA was linked to a 10.6-fold higher recurrence risk; two-year disease-free survival was 36.2% versus 92.3%.
- The WGS test found ctDNA in 15 additional patients beyond the 29 detected by the WES test.
- The test has not been cleared or approved by the US FDA.
What the Beta-CORRECT study found
According to Abbott, a single blood draw taken approximately one month after surgery was enough for the WGS-based Oncodetect test to reach 72.2% sensitivity for recurrence within two years. The WES-based test achieved 42.2% on the same measure, which Abbott describes as a 30-percent absolute improvement.
The study analyzed post-surgical samples from 279 patients, predominantly with stage II and III colorectal cancer. Abbott describes Beta-CORRECT as the first clinical validation study of the WGS Oncodetect test in patients with stage II, III and resectable stage IV colorectal cancer. It was conducted in collaboration with Dr. Takayuki Yoshino of the National Cancer Center Hospital East in Japan.
The test is tumor-informed and tracks up to 5,000 DNA variants unique to each patient's tumor. Abbott says this widens the chance of detecting residual disease when very little cancer DNA is present.
More patients detected, stronger prognostic signal
Among 157 patients tested after surgery with both methods, the WGS test detected circulating tumor DNA (ctDNA) in all 29 patients identified by the WES test, plus 15 additional patients. All of the extra detections were at levels below 20 parts per million (ppm), and 14 of them were below 10 ppm.
Abbott also reported the following prognostic results:
- Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence than ctDNA-negative patients.
- Two-year disease-free survival was 36.2% in ctDNA-positive patients versus 92.3% in ctDNA-negative patients.
- In stage II disease, patients with detectable post-surgical ctDNA had approximately 31-fold higher recurrence risk than those who were ctDNA negative. Only 2.8% of stage II patients with undetectable ctDNA had a recurrence within two years.
According to the company, detecting ctDNA after surgery was the strongest predictor of recurrence among the factors studied, and it gave information about risk beyond traditional clinical measures.
Comments from investigators and Abbott
Dr. Yoshino, principal investigator of the study, said: "The ability to identify additional patients with detectable ctDNA after surgery may help refine recurrence risk assessment beyond traditional clinical factors. Continued research will help determine how these findings can best inform patient management."
Dr. Rick Baehner, chief medical officer for precision oncology in Abbott's cancer diagnostics business, said the findings "reinforce why sensitivity matters in MRD testing, particularly after surgery when ctDNA can be difficult to detect."
The results were shown in ESMO 2026 poster 4426P. Abbott says additional patient follow-up and longitudinal data from later testing time points are expected to shed more light on the relationship between MRD, adjuvant therapy and recurrence risk over time.
About the test and what it means
Oncodetect is a whole-genome sequencing-based, tumor-informed MRD test for patients with solid tumors. It analyzes ctDNA shed into the bloodstream and reports a quantitative measure (MTM/mL), which Abbott says helps healthcare providers understand a patient's MRD status and make informed treatment decisions. The test was developed, and its performance characteristics determined, by Genomic Health, Inc. It has not been cleared or approved by the US Food and Drug Administration, and Abbott notes that performance characteristics may not apply in tumor types not included in its clinical validation.
Abbott frames the results as part of a connected approach to cancer care, linking its Cologuard colorectal cancer screening test, which it has offered for more than 12 years, with monitoring for recurrence after treatment. For clinicians, the data suggest that a more sensitive assay may identify more patients at elevated risk soon after surgery. As Dr. Yoshino stressed, how such results should guide patient management still needs further research.


